ICCM on Nasdaq

IceCure Medical

Logo: icecure-medical.com3

Israeli medical device company that raised $20.5 million in 2026 (SEC Form D). Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

$3.4MRevenue, fiscal 20254
-$15.1MNet income, fiscal 20254
Jan 2006Founded1

Compare with Nuo Therapeutics, Inc., OSR Health, Inc. or Tenon Medical, Inc., or pick any stock.

  • TickerICCM on Nasdaq1
  • Industrymedical device1
  • HeadquartersCaesarea1
  • Websiteicecure-medical.com
  • Listed onNasdaq (ICCM), Tel Aviv Stock Exchange1
  • Incorporated inIsrael5
  • Business address7 Ha'Eshel St., Pob 3163, Caesarea, 389005
  • Filer categoryNon-accelerated filer, Emerging growth company5
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

IceCure Medical image from its website
Image: icecure-medical.com3

Risks Related to Product Development and Regulatory Approval ”” for additional information).6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

36.3%Gross margin4
-446.7%Operating margin4
-445.6%Net margin4
2.7%Revenue growth, 20254
-166.4%Return on equity4
0.00×Debt to equity4
-$14.6MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Disposables brought in 61% of the revenue IceCure Medical broke down this way in fiscal 2025.

  1. Disposables$2.1M461%up 12% from 2024
  2. Systems$1.3M439%down 3% from 2024
Products and services by year
Products and services202320242025
Disposables$1.5M$1.8M$2.1M
Systems$1.5M$1.4M$1.3M

Regions

Other Countries brought in 57% of the revenue IceCure Medical broke down this way in fiscal 2025.

  1. Other Countries$1.9M457%up 33% from 2024
  2. United States$908.0K427%up 4% from 2024
  3. Japan$282.0K48%down 41% from 2024
  4. India$120.0K44%down 71% from 2024
  5. [Canada]$108.0K43%up 163% from 2024
  6. Israel$24.0K41%down 20% from 2024
Regions by year
Regions202320242025
Other Countries$1.4M$1.5M$1.9M
United States$751.0K$870.0K$908.0K
Japan$480.0K$481.0K$282.0K
India$109.0K$413.0K$120.0K
[Canada]$440.0K$41.0K$108.0K
Israel$30.0K$30.0K$24.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue22¢$2.2M
  • Research and development78¢$7.4M

Out of $3.4M in revenue.4 The company lost money this year.

Financial statements

Revenue7894$3.4M in 2025+108% since 2019
0$2.0M$4.0M$6.0M2019: $1.6M$1.6M20192020: $3.9M$3.9M2020+138%2021: $4.1M$4.1M2021+7%2022: $3.1M$3.1M2022−25%2023: $3.2M$3.2M2023+5%2024: $3.3M$3.3M2024+2%2025: $3.4M$3.4M2025+3%
Gross profit781094$1.2M in 2025+134% since 2019
0$1.0M$2.0M$3.0M2019: $524.0K$524.0K20192020: $2.4M$2.4M2020+366%2021: $2.2M$2.2M2021−10%2022: $1.4M$1.4M2022−34%2023: $1.3M$1.3M2023−10%2024: $1.5M$1.5M2024+12%2025: $1.2M$1.2M2025−16%
Operating income781094-$15.1M in 2025+216% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$4.8M-$4.8M20192020: -$4.1M-$4.1M2020−13%2021: -$9.7M-$9.7M2021+135%2022: -$16.7M-$16.7M2022+72%2023: -$15.6M-$15.6M2023−7%2024: -$15.7M-$15.7M2024+1%2025: -$15.1M-$15.1M2025−4%
Net income781094-$15.1M in 2025+231% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$4.6M-$4.6M20192020: -$3.7M-$3.7M2020−18%2021: -$9.9M-$9.9M2021+165%2022: -$17.0M-$17.0M2022+72%2023: -$14.7M-$14.7M2023−14%2024: -$15.3M-$15.3M2024+5%2025: -$15.1M-$15.1M2025−2%

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Revenues$3.4M$3.3M$3.2M
Cost of revenues$2.2M$1.8M$1.9M
Gross profit$1.2M$1.5M$1.3M
Research and development expenses$7.4M$7.1M$8.3M
Sales and marketing expenses$4.4M$6.3M$4.4M
General and administrative expenses$4.5M$3.8M$4.2M
Operating loss$15.1M$15.7M$15.6M
Finance expenses (income), net-$37.0K-$378.0K-$924.0K
Net loss and comprehensive loss$15.1M$15.3M$14.7M
Basic and diluted net loss per share (in Dollars per share)$0.24$0.30$0.32
Diluted net loss per share (in Dollars per share)$0.24$0.30$0.32
Weighted average number of shares outstanding used in computing basic and diluted net loss per share (in Shares)63.6M shares50.9M shares45.6M shares
Weighted average number of shares outstanding used in computing diluted net loss per share (in Shares)63.6M shares50.9M shares45.6M shares

Compare IceCure Medical with another company

Leadership

Who has led IceCure Medical, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Eyal Shamir2026–now

Chief financial officer

  1. Ronen Tsimerman2026
  2. Meir Peleg2026–now

Chief operating officer

  1. Shay Levav2026–now
2010201520202025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorYang Huang named Mar 31, 2026 to Jun 25, 202624

Timeline

  1. Mar 25, 2026New chief executive Eyal Shamir becomes CEO11
  2. Jan 2006Founded Founded1

Filings

288 filings to the SEC since October 2021: 7 annual reports, 22 insider forms, 9 large holders, 2 private raises, 248 other. The latest 20:

  1. Oct 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Oct 5, 20266-K CURRENT REPORT EDGAR
  3. Oct 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Sep 28, 20266-K CURRENT REPORT EDGAR
  5. Sep 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Aug 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Aug 18, 2026EFFECT EDGAR
  8. Aug 18, 2026EFFECT EDGAR
  9. Aug 17, 20264 EDGAR
  10. Aug 17, 20263 EDGAR
  11. Aug 17, 20264 EDGAR
  12. Aug 17, 20264 EDGAR
  13. Aug 17, 20264 EDGAR
  14. Aug 17, 20264 EDGAR
  15. Aug 17, 20264 EDGAR
  16. Aug 14, 2026S-8 REGISTRATION STATEMENT EDGAR
  17. Aug 14, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Aug 14, 2026SCHEDULE 13G EDGAR
  19. Aug 13, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 EDGAR
  20. Aug 13, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 4 TO FORM F-1 EDGAR

The 288 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jun 17, 2026Raised $16.5 million in a private offering of securities Form D: 1 investor so far Form D
  2. Mar 26, 2026Raised $4 million in a private offering of securities Form D: 5 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Company websiteIceCure Medical logo
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28